EU antitrust regulators to decide on Novartis, GSK deals by January 14
Reuters
Published Dec 01, 2014 07:36AM ET
EU antitrust regulators to decide on Novartis, GSK deals by January 14
BRUSSELS (Reuters) - European Union antitrust regulators will decide by Jan. 14 whether to clear two asset trade deals between Swiss drugmaker Novartis and British rival GlaxoSmithKline, the European Commission said on Monday.
Novartis is buying GSK's oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma, boosting its world No. 2 position in cancer behind Roche Holding AG.
GSK in turn is acquiring Novartis' vaccines business, excluding flu, for $5.25 billion plus potential milestone payments of up to $1.8 billion and ongoing royalties. The companies also plan a joint venture in consumer healthcare.
The Commission can either clear the deals, demand concessions if it sees potential competition issues or open a lengthy investigation into the takeovers.us
The EU antitrust watchdog last week cleared U.S. medical device maker Medtronic's $43 billion takeover of Covidien Plc on condition Covidien sell its drug-coated balloon catheter business.
(Reporting by Foo Yun Chee, editing by Louise Heavens)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.